The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

cardiokinetix.com

Founded Year

2002

Stage

Series F | Alive

Total Raised

$118.8M

Last Raised

$50M | 7 yrs ago

About CardioKinetix

CardioKinetix develops a percutaneous treatment for patients with left ventricular dilation after an anterior myocardial infarction (MI). The implantable device, called the PARACHUTE is a partitioning membrane deployed within the compromised ventricle. The PARACHUTE partitions the damaged muscle, isolating the non-functional muscle segment from the functional segment, and decreases the overall volume. Options for patients whose ventricle has enlarged are limited, with most on medical therapy and/or a cardiac resynchronization device that only benefits heart failure patients with a specific EKG pattern.

CardioKinetix Headquarter Location

925 Hamilton Avenue

Menlo Park, California, 94025,

United States

650-364-7016

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing CardioKinetix

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

CardioKinetix is included in 2 Expert Collections, including Medical Devices.

M

Medical Devices

7,913 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.

H

Health IT

7,900 items

CardioKinetix Patents

CardioKinetix has filed 31 patents.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

9/18/2015

8/25/2020

Cardiovascular physiology, Cardiac anatomy, Cardiology, Heart diseases, Congenital heart defects

Grant

Application Date

9/18/2015

Grant Date

8/25/2020

Title

Related Topics

Cardiovascular physiology, Cardiac anatomy, Cardiology, Heart diseases, Congenital heart defects

Status

Grant

Latest CardioKinetix News

Aegea Medical picks up former Cardiokinetix, Concentric Medical CEO Sainz | Personnel Moves – May 14, 2018

May 14, 2018

| Personnel Moves – May 14, 2018 May 14, 2018 Aegea Medical  said last week it tapped former Cardiokinetix prez & CEO Maria Sainz as its new president and chief executive officer, effective immediately. Sainz will replace former CEO Don Gurskis, who has held the corner office since 2013. Gurskis will remain on as member of the Redwood City, Calif.-based company’s executive management team. “Maria is a highly respected industry veteran with an exceptional track record of building and leading strong teams and growing businesses with groundbreaking, PMA-class devices. Maria’s experience and successful record in commercializing medical technologies around the world will be a significant asset as she leads Aegea into the next phase of its growth. On behalf of the Board of Directors, investors and employees, we thank Don Gurskis for his contributions which have created a solid foundation for the company’s future success. We look forward to continuing contributions from Don,” Aegea chair Paul Goeld said in a press release. Prior to joining Cardiokinetix, Sainz also served as president and CEO of Concentric Medical , and negotiated the sale of its Merci system to Stryker  (NYSE: SYK ) in 2012. Sainz has also held positions with Boston Scientific  (NYSE: BSX ) and Guidant , Aegea Medical said. “We could not be more pleased with Maria’s addition to the Aegea team. Her leadership and expertise, especially in sales and marketing, will have a big impact on Aegea’s ability to gain market share as we launch the Aegea Vapor system,” Alloy Ventures’ Dr. Doug Kelly, who was an original investor in the company, said in prepared remarks. “I am thrilled to join Aegea and am truly impressed by the company’s accomplishments. Aegea’s endometrial ablation system, the first system developed for in-office use, will accelerate the market shift to office-based treatments. The Aegea Vapor System’s best-in-class safety, simplicity and effectiveness provides physicians and patients with a much-needed new solution. I look forward to working with the Aegea team to deliver on our mission to improve the quality of lives for millions of women who suffer from this disabling condition,” Sainz said in a prepared statement. Viveve Medical said last week it lifted its former CFO Scott Durbin to the corner office, effective immediately. Durbin will also join the company’s board of directors. The move follows former CEO Patricia Scheller’s decision to step down to pursue other personal and business opportunities. Scheller will remain with the company’s board of directors. “Scott is uniquely qualified to lead Viveve into the next stage of growth given his significant operational and clinical experience, and 5-year tenure as the company’s Chief Financial Officer. We are extremely pleased to promote Scott at this important juncture for Viveve, as the company continues to solidify its position as a leader in women’s intimate health and develop its innovative CMRF technology for the treatment of Stress Urinary Incontinence. We are also delighted that Debora Jorn will be taking an active advisory role in supporting Scott as the company advances toward a potential launch in the large, unsatisfied incontinence market. The board and I want to thank Patricia Scheller for her many contributions to Viveve. She established the company and product branding, built a strong management team and led its initial development into a global business. We support her decision to step down and agree this is the opportune time for Scott to lead Viveve into its next phase of commercial growth,” board chair Dan Janney said in a press release. “I am extremely excited and honored to be chosen to lead Viveve into this next phase of growth. Viveve’s commitment to improve the intimate health and wellness of women around the world is one I continue to passionately share with our employees and stakeholders. I look forward to working more closely with Debora, the Board and the entire organization to drive the growth of the current business while rapidly advancing our development and commercialization programs in female sexual function and SUI,” Durbin said in a prepared release. Viveve also named former director Debora Jorn as its new senior advisor to the CEO. Conventus Orthopaedics  said last month it named former InfraReDx CFO Jonathan Isenburg as its new chief financial officer. During his time at Infraredx, Isenburg led the company through a dual-track initial public offering and a sale to a Nipro (TYO:  8086 ), Minneapolis-based Conventus said. Prior to joining Infraredx, Isenburg operated as a manager with RSM’s financial advisory services, and began his career as an auditor with PricewaterhouseCoopers. “I am pleased to welcome Jonathan to the Conventus team. We will benefit from his expertise and leadership as we continue to grow commercial operations and accelerate development to bring the CAGE platform technology to additional types of fractures. Jonathan is an experienced medical device industry executive who has excelled in corporate finance, strategy, business development and operations. He has a proven track record of success and we look forward to utilizing his many talents,” CEO Matthew Jewett said in a press release. “It is with much enthusiasm that I join the outstanding Conventus team who has developed true game-changing technology for the treatment of simple and complex fractures throughout the anatomy. I look forward to working with them to grow the business and bring this innovative and less invasive surgical solution to more patients,” Isenburg said in a prepared statement. Cerus  (NSDQ: CERS ) said last Friday it promoted chief technology officer Stephen Griffin to the role of president, and that Todd Derbin is no longer acting as CEO or board chair of the company or its US subsidiary. Griffin operated as CTO since joining Fremont, Calif.-based Cerus in 2014, the company said. Prior to joining Cerus, Griffin founded the medical device and tech consultancy firm Griffin Biomedical. He has also held positions as research and technology development VP at Covidien , R&D director at Nellix Endovascular , R&D director at Cordis and various research positions at Boston Scientific. “For the past four years, Stephen has been an integral part of the Cerus team, and it gives the Board great satisfaction to recognize his vast contributions through his promotion to president. In addition to inventing or co-inventing Cerus’s portfolio of interventional neuroradiology devices, including the Contour neurovascular system, as well as its intra-saccular coil assist neck bridge technology and microcatheters, Stephen has played a key role in their clinical advancement while also forging relationships with key opinion leaders and pursuing strategic collaborations. The board looks forward to the continuity of Stephen’s leadership as Cerus works to bring its novel aneurysm treatments to market while creating significant value for its investors,” lead director Sam Milstein said in a prepared statement. “I am honored to accept the role of president of Cerus Endovascular at this important time in the company’s evolution. We are working toward a number of important milestones this year, including CE Mark and FDA approval for our family of microcatheters, the first of which has been submitted for approval in the U.S. We are also working toward completion of CE Mark trial enrollment of the Contour Neurovascular System, and the initiation of activities to support an investigational device exception (IDE) study of both the Contour Neurovascular System and the intra-saccular neck bridge device technology. We believe these technologies have the potential to significantly advance the field of aneurysm therapy, and we continue to work diligently to bring these treatment options to patients who need them,” Dr. Griffin said in a press release. Cellect Biotechnology said it plans to open a US center of operations to be led by former GE Healthcare  (NYSE: GE ) executive Andrew Sabatier. During his time at GE, Sabatier served as sales and market development leader for GE Cell Therapy in the US and Canada, Israel-based Cellect said. Prior to joining GE, Sabatier served as sales VP for Biosafe America. “Cellect is a leader in Regenerative Medicine enabling technology. We see an upcoming surge in demand for stem cells as raw material for a wide range of soon to be FDA approved novel therapies. It is a multi-billion-dollar potential business and a new industry in the making. I am happy to be a part of this journey to bring 21stcentury remedies to millions of patients worldwide,” Sabatier said in a prepared release.

  • When was CardioKinetix founded?

    CardioKinetix was founded in 2002.

  • Where is CardioKinetix's headquarters?

    CardioKinetix's headquarters is located at 925 Hamilton Avenue, Menlo Park.

  • What is CardioKinetix's latest funding round?

    CardioKinetix's latest funding round is Series F.

  • How much did CardioKinetix raise?

    CardioKinetix raised a total of $118.8M.

  • Who are the investors of CardioKinetix?

    Investors of CardioKinetix include U.S. Venture Partners, Tekla Capital Management, SV Health Investors, New Leaf Venture Partners, Panorama Capital and 7 more.

  • Who are CardioKinetix's competitors?

    Competitors of CardioKinetix include Ancora Heart, Respicardia, Cayenne Medical, MiCardia, Paracor Medical and 12 more.

You May Also Like

C
Cardiac Power

Cardiac Power is a non-blood-contacting left ventricular assist device for the treatment of congestive heart failure

C
Chase Medical

Chase Medical is developing medical technology for treating congestive heart failure. Chase Medical is developing a device called the Mannequin which aims to help the heart maintain its shape while going through reconstruction of the left ventricle.

C
CoRepair

CoRepair, Inc. is developing a radiofrequency (RF) device system for the treatment of congestive heart failure.

C
CardioMetrix

CardioMetrix is a medical device company developing implantable technologies to assist physicians in managing patients suffering from congestive heart failure (CHF).

V
Viacor

Viacor is a development stage company dedicated to pioneering catheter-based techniques for the treatment of congestive heart failure.

B
Bio Control Medical

Bio Control Medical offers implantable devices for the treatment of incontinence and congestive heart failure.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.